Jan 20, 2026 06:41AM
Dec 17, 2025 07:00AM
Dec 17, 2025 07:00AM
Nov 20, 2025 07:30AM
Sep 4, 2025 07:02AM
Sep 4, 2025 07:00AM
Aug 15, 2025 07:00AM Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
May 23, 2025 07:15AM
May 1, 2025 07:09AM
May 1, 2025 07:00AM
Apr 17, 2025 08:42AM
Apr 17, 2025 08:40AM
Nov 20, 2024 07:02AM
Nov 20, 2024 07:00AM Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
Nov 15, 2024 07:00AM
Aug 17, 2024 11:27AM
Aug 16, 2024 07:00AM
Jul 25, 2024 07:03AM
Jul 25, 2024 07:00AM
Jul 15, 2024 07:01AM
Jul 15, 2024 07:00AM Sol-Gel Technologies Announces Management Realignment
May 28, 2024 07:04AM
May 28, 2024 07:00AM
May 20, 2024 07:00AM
May 16, 2024 06:00AM
May 16, 2024 06:00AM
Apr 1, 2024 07:03AM
Apr 1, 2024 07:00AM Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Mar 13, 2024 07:00AM
Nov 30, 2023 07:00AM
Nov 28, 2023 08:06AM
Nov 9, 2023 07:00AM
Aug 30, 2023 08:00AM
Aug 10, 2023 07:00AM
Jun 6, 2023 07:30AM Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
Jun 6, 2023 07:04AM
Jun 6, 2023 07:00AM
May 12, 2023 07:00AM
Mar 20, 2023 07:00AM
Mar 10, 2023 07:00AM
Jan 27, 2023 07:29AM
Jan 27, 2023 07:29AM Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
Jan 27, 2023 07:00AM
Jan 27, 2023 07:00AM
Aug 29, 2022 06:27AM
Aug 4, 2022 06:00AM
Jun 2, 2022 08:00AM
May 13, 2022 07:00AM
Apr 25, 2022 07:04AM Sol-Gel Technologies Ltd. (SLGL) and Galderma Announce FDA Approval of EPSOLAY
Apr 25, 2022 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All